Laura Prendergast
Stock Analyst at Stifel
(2.54)
# 2,221
Out of 5,116 analysts
14
Total ratings
53.85%
Success rate
4.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Initiates: Buy | $15 | $8.67 | +73.01% | 1 | Dec 4, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $5.40 | +122.22% | 1 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $104.10 | +29.69% | 2 | Nov 17, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $2.59 | +208.88% | 2 | Oct 16, 2025 | |
| RVMD Revolution Medicines | Reinstates: Buy | $85 | $80.75 | +5.26% | 3 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $3.48 | +14.94% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $38.88 | -58.85% | 1 | Oct 16, 2025 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $1.84 | +769.57% | 2 | Aug 14, 2024 |
Tango Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $15
Current: $8.67
Upside: +73.01%
Foghorn Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $12
Current: $5.40
Upside: +122.22%
Nuvalent
Nov 17, 2025
Maintains: Buy
Price Target: $115 → $135
Current: $104.10
Upside: +29.69%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $2.59
Upside: +208.88%
Revolution Medicines
Oct 16, 2025
Reinstates: Buy
Price Target: $85
Current: $80.75
Upside: +5.26%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $3.48
Upside: +14.94%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $38.88
Upside: -58.85%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $1.84
Upside: +769.57%